In an ex parte ad interim injunction order
issued on June 17, 2013 in suit instituted by Merck against Aprica Pharma with
respect to Sitagliptin (IN209816), the Delhi High Court has restrained Aprica from
“selling, distributing, advertising,
exporting, offering for sale and in any other manner, directly or
indirectly, dealing in any product that infringes the subject matter of the” patent.
The next date in the matter is August 13, 2013.
Earlier in April, we had reported the denial of interim injunction with respect to the same drug against Glenmark, in which an appeal is pending before Justice Ravindra Bhat. We will keep the readers posted on the developments in the Suits and appeal.
I thank a dear friend for sharing this development with me.
Earlier in April, we had reported the denial of interim injunction with respect to the same drug against Glenmark, in which an appeal is pending before Justice Ravindra Bhat. We will keep the readers posted on the developments in the Suits and appeal.
I thank a dear friend for sharing this development with me.
Dear JSD:
ReplyDeleteWhat is confusing is that there is no discussion of the earlier Glenmark (no) injunction in the current order from the vacation batch.
- dear friend
Dear JSD,
ReplyDeleteLong time no post!!
Sorry :-) Have been really tied up with a lot of work and "extra-curricular" commitments :-) will surely make up for it soon! The idea is to write on slightly different issues after a bit of reading.
DeleteSai.
looking forward to it:)
ReplyDeleteI thought blogging was "extra curricular" ;)
For me, blogging is "curricular" in a way :-)
Delete